Loading…
Holding company for Samsung Bioepis, which develops and sells biosimilar drugs worldwide.
Holding company for Samsung Bioepis, which develops and sells biosimilar drugs worldwide.
Holds Samsung Bioepis, which sells biosimilars, near-copies of biologic drugs whose patents have expired, mostly through commercial partners in the US and Europe that handle sales. Bioepis is the main earner. Epis was split out as a holding company from Samsung Biologics in 2025.
In one line: A holding company over a Sandoz-style biosimilar maker.
Moat: narrow (regulatory licence, process know-how). Biosimilar approvals and manufacturing scale-up are costly barriers for new entrants.
Headquarters: Incheon, South Korea · Founded: 2025 · Employees: 9
Size Samsung Epis (0126Z0.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $6.39B, the 67th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩349,500 on 6 Nov 2026.
Performance Over six months the shares fell 35.6%, against +0.1% for the median peer and -24.5% for the South Korea market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth The operating margin is -25.3% (peer median 17.5%).
Valuation It trades at 24.0× forward earnings against a peer median of 27.4× (8th cheapest of 16).
Capital Return on invested capital runs 6.5 points below its cost of capital (5.7% WACC).
Next results Next results expected around 1 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | |
|---|---|---|
| Revenue | n/a | ₩252B |
| Revenue growth | — | — |
| Gross profit | n/a | ₩88.6B |
| EBITDA | n/a | ₩5.34B |
| Net income | n/a | -₩31.4B |
| Free cash flow | n/a | -₩110B |
| Capital expenditure | n/a | ₩40.0B |
| Total debt | n/a | ₩378B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Samsung Epis 0126Z0.KS | $6.39B | -36% | n/a | -25% | 24.0× | n/a |
| Sandoz SDZ.SW | $44.4B | +24% | +1% | 15% | 25.3× | 7.9% |
| Celltrion 068270.KS | $34.3B | +10% | +40% | 32% | 34.1× | 8.3% |
| Viatris VTRS | $22.9B | +17% | +5% | 10% | 7.5× | 12.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 0126Z0.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.3% | +2.4% | 3rd lowest of 21 |
| 6-month return | -35.6% | +0.1% | 2nd lowest of 20 |
| Distance from 52-week high | -54.8% | -13.1% | lowest of 21 |
| Operating margin | -25.3% | 17.5% | 2nd lowest of 18 |
| Forward P/E | 24.0× | 27.4× | 8th cheapest of 16 |
| ROIC minus cost of capital | -6.5 pp | +1.9 pp | 7th lowest of 20 |
| Net debt / EBITDA | 46.2× | 0.0× | most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Samsung Epis 0126Z0.KS | South Korea | $6.39B | -36% | n/a | -25% | 24.0× | n/a | n/a |
| Gan & Lee Pharmaceuticals 603087.SS | China | $6.40B | +21% | +14% | 20% | 29.7× | n/a | n/a |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% | +18.4% |
| Biocon BIOCON.NS | India | $6.28B | -4% | +6% | 8% | 56.4× | n/a | n/a |
| Ionis Pharmaceuticals IONS | United States | $6.55B | -48% | -7% | -68% | n/a | n/a | n/a |
| Belite Bio, Inc. ADR BLTE | United States | $6.20B | 0% | n/a | n/a | n/a | n/a | n/a |
| Alkem Laboratories ALKEM.NS | India | $6.67B | -5% | +13% | 17% | 27.4× | 24.3% | +10.7% |
| Ligand Pharmaceuticals LGND | United States | $6.12B | +38% | +1% | 14% | 28.0× | 57.8% | +7.5% |
| Mirum Pharmaceuticals MIRM | United States | $6.12B | -13% | +42% | -21% | n/a | n/a | n/a |
| Oruka Therapeutics ORKA | United States | $6.81B | +59% | n/a | n/a | n/a | n/a | n/a |
| Abbott India ABBOTINDIA.NS | India | $5.93B | -1% | +6% | 28% | 32.4× | 11.4% | +10.0% |
| RemeGen 688331.SS | China | $6.90B | -26% | +272% | 61% | 11.9× | 2.8% | +303.3% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.90B | -6% | +39% | 47% | 13.8× | 1.8% | +519.6% |
| ONO Pharmaceutical 4528.T | Japan | $7.01B | +2% | -2% | 22% | 14.7× | -8.2% | +10.8% |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 17.7× | 15.2% | +8.7% |
| Veradermics MANE | United States | $5.80B | +31% | n/a | n/a | n/a | n/a | n/a |
| Apotex Health APTX.TO | Canada | $5.62B | n/a | +4% | 32% | 18.6× | -13.5% | +4.2% |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 14.0× | -2.7% | +5.3% |
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 33.1× | n/a | n/a |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 61.7× | 9.9% | +45.5% |
| Gland Pharma GLAND.NS | India | $5.53B | +69% | +18% | 20% | 39.0× | 28.0% | +13.3% |